docetaxel anhydrous has been researched along with Fallopian Tube Neoplasms in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (40.00) | 29.6817 |
| 2010's | 18 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Becker, DA; Bevis, KS; Leath, CA; Smith, BQ; Walters-Haygood, CL | 1 |
| Armstrong, DK; Coleman, RL; Phillips, M; Weil, SC; White, AJ | 1 |
| Apte, SM; Gonzalez-Bosquet, J; Havrilesky, LJ; Herschberger, A; Judson, PL; Lancaster, JM; Lapolla, J; Lin, HY; Secord, AA; Wenham, RM | 1 |
| Bell, MC; Braly, P; Childs, BH; Drake, RD; Einstein, MH; Herzog, TJ; Hines, JF; Monk, BJ; Roman, LD; Rose, PG; Secord, AA; Wenham, RM | 1 |
| Anderson, GL; Bonebrake, AJ; Chambers, SK; Coleman, RL; Delmore, JE; Hu, W; Markman, M; Moon, J; Sood, AK | 1 |
| DePoint Christensen, R; Havsteen, H; Herrstedt, J; Kristensen, G; Lund, B; Maenpaa, J; Mirza, MR; Wang, Y | 1 |
| Donovan, H; Edwards, RP; Keeler, AW; Li, R; O'Neal, S; Petschauer, JS; Taylor, SE; Zamboni, WC; Zorn, KK | 1 |
| Alpert, Y; Bruchim, I; Fishman, A; Piura, E; Sade, D; Weeg, N | 1 |
| Chi, DS; Gardner, GJ; Long Roche, K; Mueller, JJ; O'Cearbhaill, RE; Schlappe, BA; Sonoda, Y; Zivanovic, O | 1 |
| Afors, K; Akladios, C; Baldauf, JJ; Hummel, M; Kurtz, JE; Lecointre, L; Marchal, F; Mathelin, C; Petit, T; Rebstock, LE; Schrot-Sanyan, S | 1 |
| Groe, R; Grothey, A; Kantelhardt, EJ; Kegel, T; Koelbl, H; Mueller, LP; Schmoll, HJ; Seliger, G; Strauss, HG; Thomssen, C | 1 |
| Ahn, EH; Eno, ML; Im, DD; Matsuo, K; Rosenshein, NB; Shahzad, MM; Sood, AK | 1 |
| Goff, B; Holmberg, LA; Veljovich, D | 1 |
| Arimoto, T; Kawana, K; Nakagawa, S; Oda, K; Taketani, Y; Yasugi, T | 1 |
| Havrilesky, LJ; Higgins, RV; Holloway, RW; Kohler, MF; Lewandowski, GS; Nycum, LR; Pokrzywinski, R; Puls, LE; Revicki, DA; Secord, AA | 1 |
| Coleman, RL; Duska, LR; Garcia, ME; Heymach, JV; Iyer, RB; Jackson, EF; Jaffe, R; Kamat, AA; Kundra, V; Miller, DL; Modesitt, SC; Ng, CS; Ramirez, PT; Schmeler, KM; Sood, AK | 1 |
| Ota, T; Takeshima, N; Takizawa, K | 1 |
| de Graaf, H; de Munck, L; Erdkamp, FLG; Hoekman, K; Hollema, H; Lalisang, RI; Polee, M; Reyners, AKL; Schaapveld, M; Smit, WM; van Vugt, MATM; Willemse, PHB; Wymenga, ANM | 1 |
| Armstrong, DK; DiSilvestro, PA; Fracasso, PM; Gould, N; Mannel, RS; Sill, MW; Thaker, PH; Waggoner, SE; Walker, JL; Yamada, SD | 1 |
| Belinson, J; Kulp, B; Markman, M; Peterson, G; Webster, K; Zanotti, K | 2 |
| Furugen, Y; Hata, A; Hata, N; Hata, Y; Kurokawa, A; Mitsuhashi, N; Nishihara, S; Sone, Y | 1 |
| Atkinson, T; Berkenblit, A; Cannistra, SA; Krasner, CN; Matulonis, UA; Mezzetti, L; Penson, RT; Roche, M; Seiden, MV | 1 |
| Asai, S; Dokoh, J; Ishikawa, M; Komiyama, S; Mikami, M; Tsuji, H | 1 |
| Chan, S; Clamp, AR; Cruickshank, D; Hindley, A; Jayson, GC; Ledermann, J; Mäenpää, J; Sorbe, B; Vasey, P; Welch, R; Wilkinson, PM | 1 |
| Atkinson, R; Coleman, R; Kaye, S; Lewsley, L; Osborne, R; Parkin, D; Paul, J; Reed, NS; Rustin, GJ; Symonds, R; Vasey, PA | 1 |
| Baumgart, A; Henze, A; Karbe, I; Koelbl, H; Strauss, HG; Teichmann, A; Thomssen, C | 1 |
| Carty, K; Gabra, H; Gore, M; Guastalla, JP; Kaye, S; Lauraine, EP; Paul, J; Rustin, G; Vasey, PA; Wilson, R | 1 |
| Atkinson, EN; Guedes, Ed; Kavanagh, JJ; Kudelka, AP; Nelson-Taylor, T; Rogers, R; Sittisomwong, T; Steger, M; Verschraegen, CF; Vincent, M | 1 |
| Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K | 1 |
21 trial(s) available for docetaxel anhydrous and Fallopian Tube Neoplasms
| Article | Year |
|---|---|
Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2019 |
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2013 |
A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids | 2013 |
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Taxoids | 2014 |
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Quinazolines; Taxoids; Treatment Outcome | 2014 |
A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Ovarian Epithelial; Chemotherapy-Induced Febrile Neutropenia; Disease Progression; Disease-Free Survival; Docetaxel; Drug Screening Assays, Antitumor; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Prospective Studies; Somatosensory Disorders; Taxoids; Treatment Outcome; Young Adult | 2014 |
Phase I study of intravenous (IV) docetaxel and intraperitoneal (IP) oxaliplatin in recurrent ovarian and fallopian tube cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Taxoids | 2015 |
High Efficacy and Low Toxicity of the Modified Docetaxel and Carboplatin Protocol in Patients with Recurrent Ovarian Cancer-A Phase 2 Cohort Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cohort Studies; Cystadenocarcinoma, Serous; Docetaxel; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2016 |
Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Risk Factors; Taxoids; Treatment Outcome; Young Adult | 2009 |
Unexpected gastrointestinal toxicity from Docetaxel/Carboplatin/Erlotinib followed by maintenance Erlotinib treatment for newly diagnosed stage III/IV ovarian cancer, primary peritoneal, or fallopian tube cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines; Taxoids | 2011 |
Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Prospective Studies; Quality of Life; Recurrence; Severity of Illness Index; Taxoids | 2011 |
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Taxoids; Time Factors; Treatment Outcome; United States | 2011 |
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the Do
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrazoles; Sulfonamides; Taxoids | 2012 |
A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2012 |
A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Serous; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids | 2004 |
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboplatin; Carcinoma; Disease Progression; Docetaxel; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Dyspnea; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids | 2007 |
A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Humans; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Quinazolines; Taxoids | 2008 |
Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Statistics, Nonparametric; Survival Analysis; Taxoids | 2000 |
Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2001 |
9 other study(ies) available for docetaxel anhydrous and Fallopian Tube Neoplasms
| Article | Year |
|---|---|
Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Docetaxel; Fallopian Tube Neoplasms; Female; Guideline Adherence; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Taxoids | 2016 |
Does the Number of Neoadjuvant Chemotherapy Cycles before Interval Debulking Surgery Influence Survival in Advanced Ovarian Cancer?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Taxoids | 2016 |
Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Brachytherapy; Brain Neoplasms; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Combined Modality Therapy; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2011 |
Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carboplatin; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2003 |
Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Topotecan | 2004 |
[Combination chemotherapy with docetaxel+carboplatin in the treatment of cancer of the ovary and fallopian tube].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Edema; Fallopian Tube Neoplasms; Female; Humans; Leukopenia; Middle Aged; Neutropenia; Ovarian Neoplasms; Peripheral Nervous System Diseases; Taxoids | 2004 |
A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Docetaxel; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Platinum Compounds; Taxoids; Treatment Outcome | 2005 |